Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 5

1.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N.

N Engl J Med. 2010 Jun 3;362(22):2053-65. doi: 10.1056/NEJMoa0909638.

2.

Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?

Perez EA.

Curr Oncol Rep. 2003 Jan;5(1):66-71. Review.

PMID:
12493153
3.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

Ann Oncol. 2003 Jun;14(6):833-42. Review.

4.

Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.

Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT.

JAMA Oncol. 2015 Dec;1(9):1311-8. doi: 10.1001/jamaoncol.2015.3062. Review.

PMID:
26402167
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk